Blay JY, Kang YK, Nishida T, et al. Gastrointestinal stromal tumours. Nat Rev Dis Primers. 2021;7:22.

Article  PubMed  Google Scholar 

Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.

Article  CAS  PubMed  Google Scholar 

Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–10.

Article  CAS  PubMed  Google Scholar 

Keung EZ, Raut CP. Management of gastrointestinal stromal tumors. Surg Clin North Am. 2017;97(2):437–52. https://doi.org/10.1016/j.suc.2016.12.001.

Article  PubMed  Google Scholar 

Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.

Article  CAS  PubMed  Google Scholar 

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38. https://doi.org/10.1016/S0140-6736(06)69446-4.

Article  CAS  PubMed  Google Scholar 

Demetri GD, Reichardt P, Kang YK, Blay J-Y, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302. https://doi.org/10.1016/S0140-6736(12)61857-1.

Article  CAS  PubMed  Google Scholar 

Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923–34. https://doi.org/10.1016/S1470-2045(20)30168-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang YK, George S, Jones RL, et al. Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III study. J Clin Oncol. 2021;39:3128–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, et al. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2022;33(9):959–67. https://doi.org/10.1016/j.annonc.2022.05.518.

Article  CAS  PubMed  Google Scholar 

Lee JH, Kim Y, Choi JW, et al. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. J Gastrointestin Liver Dis. 2013;22:413–8.

PubMed  Google Scholar 

Kunimasa K, Sugimoto N, Yamasaki T, Kukita Y, Fujisawa F, Inoue T, et al. Real-world assessment of comprehensive genome profiling impact on clinical outcomes: a single-institution study in Japan. Cancer Med. 2024;13(18):e70249. https://doi.org/10.1002/cam4.70249.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carr A, Jackson JB, Coldren C, Chandra P, Koohestani F, Shiller M, et al. Tumor diagnosis recharacterization enabled by comprehensive genomic profiling to guide precision medicine strategy. NPJ Precis Oncol. 2025;9(1):149. https://doi.org/10.1038/s41698-025-00942-5.

Article  PubMed  PubMed Central  Google Scholar 

Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci. 2019;110(4):1480–90. https://doi.org/10.1111/cas.13969.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Judson I, Jones RL, Wong N, et al. Gastrointestinal stromal tumour (GIST): British sarcoma group clinical practice guidelines. Br J Cancer. 2025;132:1–10.

Article  PubMed  Google Scholar 

Fujii H, Hirano H, Shiraishi K, et al. Comprehensive genomic assessment of advanced-stage GI stromal tumors using the Japanese National Center for Cancer Genomics and Advanced Therapeutics Database. JCO Precis Oncol. 2024;8:e2400284.

Article  PubMed  Google Scholar 

Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Milbury CA, Creeden J, Yip WK, et al. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE. 2022;17(3):e0264138. https://doi.org/10.1371/journal.pone.0264138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.

Article  PubMed  PubMed Central  Google Scholar 

Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, et al. Analytical validation of a hybrid capture–based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. J Mol Diagn. 2018;20(5):686–702. https://doi.org/10.1016/j.jmoldx.2018.05.004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woodhouse R, Li M, Hughes J, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE. 2020;15(9):e0237802. https://doi.org/10.1371/journal.pone.0237802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishida T, Naito Y, Takahashi T, et al. Molecular and clinicopathological features of KIT/PDGFRA wild‐type gastrointestinal stromal tumors. Cancer Sci. 2024;115(3):894–904. https://doi.org/10.1111/cas.16058.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klug LR, Khosroyani HM, Kent JD, et al. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol. 2022;19:328–41.

Article  PubMed  PubMed Central  Google Scholar 

Kays JK, Sohn JD, Kim BJ, et al. Approach to wild-type gastrointestinal stromal tumors. Transl Gastroenterol Hepatol. 2018;3:92.

Article  PubMed  PubMed Central  Google Scholar 

Malone ER, Oliva M, Sabatini PJB, et al. Molecular profiling for precision cancer therapies. Genome Med. 2020;12:8.

Article  PubMed  PubMed Central  Google Scholar 

Volders PJ, Aftimos P, Dedeurwaerdere F, et al. A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer. NPJ Precis Oncol. 2025;9(1):66. https://doi.org/10.1038/s41698-025-00858-0.

Article  PubMed  PubMed Central  Google Scholar